Results 121 to 130 of about 2,379 (179)

Clinical Outcomes in Concurrent Cohorts of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA)-Treated versus ELX/TEZ/IVA-Ineligible Individuals with Cystic Fibrosis in the US during COVID-19. [PDF]

Pulm Ther
Merlo CA, Romdhani H, DerSarkissian M, Muthukumar A, McGarry LJ, Lou Y, Van Brunt K.   +6 more
europepmc   +1 more source

Correction to: Improved quality of life in cystic fibrosis patients observed up to 36 months after starting Elexacaftor/Tezacaftor/Ivacaftor treatment. [PDF]

J Patient Rep Outcomes
Buniotto F, Tridello G, De Scolari A, Meneghelli I, Pintani E, Perobelli S, Cipolli M.   +6 more
europepmc   +1 more source

Respiratory Oscillometry and Multimodal Lung Function Assessment of Elexacaftor/Tezacaftor/Ivacaftor Response in Children and Young Adults With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kogias C, Sopiadou A, Fouzas S, Vantsi P, Chrysochoou EA, Desli E, Galogavrou M, Gasparis N, Hatziagorou E.   +8 more
europepmc   +1 more source

Modulation of immune responses by elexacaftor/tezacaftor/ivacaftor therapy in cystic fibrosis: data from a compassionate use program. [PDF]

Respir Res
Lucca F, Pianazzola A, Meneghelli I, Catanzaro G, Sabbioni G, Tridello G, Hristodor AM, De Luca E, Menichetti G, Breveglieri G, Altieri MT, Bordicchia M, Fabrizzi B, Ferretti E, Lippi G, Ros M, Borgatti M, Cipolli M, Bezzerri V.   +18 more
europepmc   +1 more source

Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: results from the real-world MODUL-CF study. [PDF]

ERJ Open Res
Colin L, Delaup V, Le Bourgeois M, Neve V, Wizla-Derambure N, Ioan IC, Tatopoulos A, Kieffer S, Blonde A, Bokov P, Houdoin V, Le Clainche L, Barzic A, Ohlmann C, Toin T, Perrin T, Coutier L, Abou Taam R, Bonnel AS, Rignani A, Feghali H, Bui S, Fayon M, Letierce A, Sermet-Gaudelus I, Reix P.   +25 more
europepmc   +1 more source

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fecal Elastase-1 in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Sankararaman S, Prunty L, Pamer C, Thavamani A, Roesch E, Schindler T.   +5 more
europepmc   +1 more source

Cutaneous Adverse Effects of Elexacaftor-Tezacaftor-Ivacaftor: A Single Center Cohort Study on Acne Severity in Adults With Cystic Fibrosis. [PDF]

J Cosmet Dermatol
Smith AD, Lyons CE, Somerville L, Flowers RH, Kaplan E, Albon D.   +5 more
europepmc   +1 more source

Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.

Australian prescriber
openaire   +1 more source

Real-World Evaluation of Outcomes and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Pediatric Patients With Cystic Fibrosis: A Retrospective Study. [PDF]

Clin Transl Sci
Perrotta N, Fiorito LA, Gentile R, Vescovo R, Piciocchi A, Troiani P, Poscia R, Cimino G.   +7 more
europepmc   +1 more source

Systemic and airway T cell dynamics with influenza-specific immune recovery by cystic fibrosis elexacaftor/tezacaftor/ivacaftor therapy. [PDF]

Respir Res
Mouchtaridi E, Kowalik A, Raineri EJM, Humbert M, Jägerstedt J, Bojarlind M, Nilsson K, Flodström-Tullberg M, Pincikova T, Sandberg JK.   +9 more
europepmc   +1 more source